MediciNova company info

What does MediciNova do?
MediciNova (NASDAQ:MNOV) is a biopharmaceutical company primarily engaged in the development of novel therapeutic products to address the unmet medical needs in the treatment of diseases with a focus on neurology. Their operations cover a range of activities from drug development to clinical trials, aiming to bring innovative treatments to market. MediciNova's projects include work on therapies for diseases such as multiple sclerosis, chronic obstructive pulmonary disease (COPD), and amyotrophic lateral sclerosis (ALS), among others. The company's objectives revolve around leveraging its proprietary drug discovery platform to accelerate the development of these treatments, improving patient outcomes, and creating shareholder value by advancing its pipeline of potential therapies towards commercialization.
MediciNova company media
Company Snapshot

Is MediciNova a public or private company?

key
Ownership
Public

How many people does MediciNova employ?

people
Employees
13

What sector is MediciNova in?

pie chart
Sector
Health Care

Where is the head office for MediciNova?

location pin
Head Office
La Jolla, United States

What year was MediciNova founded?

founded flag
Year Founded
2000
What does MediciNova specialise in?
/Biopharmaceutical Company /Neurological Therapies /Pulmonary Diseases /MN-166 (ibudilast) /MN-001 (tipelukast) /Clinical-Stage Research

What are the products and/or services of MediciNova?

Overview of MediciNova offerings
Ibudilast (MN-166) aimed at treating progressive multiple sclerosis, demonstrating potential in reducing neurological decay.
MN-001 (tipelukast) targets fibrotic diseases such as idiopathic pulmonary fibrosis, showing promise in reducing fibrosis.
MN-029 (denibulin) focuses on combating solid tumor cancers, including efforts towards halting tumor growth.
MN-221 (bedoradrine) serves as a treatment for acute exacerbations of asthma, improving breathing in clinical studies.
MN-166 (ibudilast) also explored for its effectiveness in treating amyotrophic lateral sclerosis, potentially slowing disease progression.

Who is in the executive team of MediciNova?

MediciNova leadership team
  • Dr. Yuichi  Iwaki M.D., Ph.D.
    Dr. Yuichi Iwaki M.D., Ph.D.
    Co-Founder, President, CEO & Executive Director
  • Dr. Kazuko  Matsuda M.D., M.P.H., Ph.D.
    Dr. Kazuko Matsuda M.D., M.P.H., Ph.D.
    Chief Medical Officer & Director
  • Mr. Jason J. Kruger CPA
    Mr. Jason J. Kruger CPA
    CFO & Principal Financial Officer
  • Dr. David H. Crean M.B.A., Ph.D.
    Dr. David H. Crean M.B.A., Ph.D.
    Chief Business Officer
  • Mr. John  O'Neil CPA
    Mr. John O'Neil CPA
    Controller